Research Paper Volume 15, Issue 9 pp 3331—3355
In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers
Figure 6. CD115+ cells are targeted by zoledronic acid. (A) Percent CD115+ cells are significantly reduced after zoledronic acid treatment (unpaired t-test, p<0.001). (B) The median expression in the vehicle vs. zoledronic acid samples shows a significant downregulation of p16 (p=0.0001), p21 (p<0.05) and the SASP markers IL1B (p<0.05) and PAI1/SERPINE1 (p<0.001) (two-way ANOVA with FDR correction for multiple comparisons, method by Benjamini, Krieger and Yekutieli). N=10 mice in the control and n=10 in the zoledronic acid group.